Search results for: MOUSE ANTI BENZODIAZEPINES-MONOCLONAL ANTIBODY
#38648067 
2024/04/22
To Up
Anti-tumor activity of a novel LAIR1 antagonist in combination with anti-PD-1 to treat collagen-rich solid tumors.
WB Leticia Rodriguez, Jiawei Huang, Laura Gibson, Jared J Fradette, Hung-I H Chen, Kikuye Koyano, Czrina Cortez, Betty Li, Carmence Ho, Amir M Ashique, Vicky Y Lin, Suzanne Crawley, Julie M Roda, Peirong Chen, Bin Fan, Jeong Kim, James Sissons, Jonathan Sitrin, Daniel D Kaplan, Don L Gibbons, Lee B Rivera
2896 related Products with: Anti-tumor activity of a novel LAIR1 antagonist in combination with anti-PD-1 to treat collagen-rich solid tumors.
100ug100ug100ug Lyophilized100μg100ug100ug Lyophilized100ug Lyophilized100ug100ug100ug Lyophilized100ug Lyophilized100ul
Related Pathways
-
No related Items
#38645250 2024/04/03
To Up
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.
IEmmanuel M Gabriel, Brian Necela, Deborah Bahr, Sneha Vivekanandhan, Barath Shreeder, Sanjay Bagaria, Keith L Knutson
1868 related Products with: Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.
100 UG100ug Lyophilized100ug100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug100ug Lyophilized
Related Pathways
-
No related Items
#38645147 2024/04/12
To Up
Monoclonal antibodies derived from B cells in subjects with cystic fibrosis reduce burden in mice.
(PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across 3 donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.Malika Hale, Kennidy K Takehara, Christopher D Thouvenel, Dina A Moustafa, Andrea Repele, Mary F Fontana, Jason Netland, Sharon McNamara, Ronald L Gibson, Joanna B Goldberg, David J Rawlings, Marion Pepper
1164 related Products with: Monoclonal antibodies derived from B cells in subjects with cystic fibrosis reduce burden in mice.
100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100 μg100.00 ug100 μg100 μg100.00 ug
Related Pathways
#38644978 2024/03/26
To Up
Estradiol induces bone osteolysis in triple-negative breast cancer via its membrane-associated receptor ERα36.
Triple-negative breast cancer (TNBC) is thought to be an estradiol-independent, hormone therapy-resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We identified a membrane-bound splice variant, ERα36, in TNBC cells that responds to estrogen (E) and may contribute to bone osteolysis. We demonstrated that the MDA-MB-231 TNBC cell line, which expresses ERα36 similarly to MCF7 cells, is responsive to E, forming osteolytic tumors in vivo. MDA-MB-231 cells activate osteoclasts in a paracrine manner. Conditioned media (CM) from MDA-MB-231 cells treated with bovine serum albumin-bound E (E-BSA) increased activation of human osteoclast precursor cells; this was blocked by addition of anti-ERα36 antibody to the MDA-MB-231 cultures. Osteoclast activation and bone resorption genes were elevated in RAW 264.7 murine macrophages following treatment with E-BSA-stimulated MDA-MB-231 CM. E and E-BSA increased phospholipase C (PLC) and protein kinase C (PKC) activity in MDA-MB-231 cells. To examine the role of ERα36 signaling in bone osteolysis in TNBC, we used our bone-cancer interface mouse model in female athymic homozygous Foxn1 mice. Mice with MDA-MB-231 tumors and treated with tamoxifen (TAM), E, or TAM/E exhibited increased osteolysis, cortical bone breakdown, pathologic fracture, and tumor volume; the combined E/TAM group also had reduced bone volume. These results suggest that E increased osteolytic lesions in TNBC through a membrane-mediated PLC/PKC pathway involving ERα36, which was enhanced by TAM, demonstrating the role of ERα36 and its membrane-associated signaling pathway in bone tumors. This work suggests that ERα36 may be a potential therapeutic target in patients with TNBC.D Joshua Cohen, Cydney D Dennis, Jingyao Deng, Barbara D Boyan, Zvi Schwartz
2615 related Products with: Estradiol induces bone osteolysis in triple-negative breast cancer via its membrane-associated receptor ERα36.
Related Pathways
#38643548 2024/01/23
To Up
Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action.
TYoko Nagai, Masataka Oitate, Takahiro Shibayama, Hideo Takakusa, Nobuaki Watanabe
2586 related Products with: Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action.
100 1 kit
Related Pathways
-
No related Items